Huapont Life Sciences Income Statement

Financials in millions CNY. Fiscal year is January - December.

Millions CNY. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Sep '25 Sep 30, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Jan '23 Jan 1, 2023	Jan '22 Jan 1, 2022	Jan '21 Jan 1, 2021
Operating Revenue	11,684	11,508	11,409	13,021	12,290	10,732
Other Revenue	156.83	156.83	186.02	211.45	141.06	143.9
Revenue	11,841	11,665	11,595	13,232	12,431	10,876
Revenue Growth (YoY)	1.63%	0.60%	-12.38%	6.44%	14.29%	7.78%
Cost of Revenue	7,921	7,827	7,208	7,971	7,759	6,469
Gross Profit	3,920	3,838	4,387	5,261	4,672	4,407
Selling, General & Admin	2,212	2,259	2,550	2,904	2,753	2,579
Research & Development	355.6	375.32	419.14	385.24	329.47	324.35
Other Operating Expenses	112.51	114.96	103.47	89.41	80.78	61.02
Operating Expenses	2,720	2,770	3,080	3,386	3,188	2,929
Operating Income	1,200	1,068	1,307	1,875	1,484	1,478
Interest Expense	-310.66	-349.97	-343.7	-434.01	-461.68	-561.07
Interest & Investment Income	82.2	69.66	92.75	529.44	380.87	323
Currency Exchange Gain (Loss)	29.81	29.81	46.5	153.25	-31.74	-76.11
Other Non Operating Income (Expenses)	27.01	-32.98	-43.03	-42.16	-55.59	-87.77
EBT Excluding Unusual Items	1,029	784.79	1,059	2,082	1,316	1,076
Impairment of Goodwill	-707.56	-707.56	-208.16	-491.85	-29.36	-
Gain (Loss) on Sale of Investments	-140.4	-194.06	1.2	-4.84	8.52	10.26
Gain (Loss) on Sale of Assets	16.86	3.75	28.11	-21.26	-22.43	2.2
Asset Writedown	-100.28	-108.59	-88.96	-31.51	-93.3	-24.15
Other Unusual Items	61.16	61.16	101.04	90.16	101.87	100.44
Pretax Income	158.39	-160.51	892.39	1,623	1,281	1,165
Income Tax Expense	206.66	182.09	215.46	495.49	361.04	270.08
Earnings From Continuing Operations	-48.28	-342.59	676.93	1,127	920.2	895.01
Minority Interest in Earnings	-90.87	43.6	-374.81	-693.72	-252.4	-243.27
Net Income	-139.15	-298.99	302.12	433.48	667.81	651.73
Net Income to Common	-139.15	-298.99	302.12	433.48	667.81	651.73
Net Income Growth	-	-	-30.30%	-35.09%	2.47%	5.08%
Shares Outstanding (Basic)	1,973	1,975	1,980	1,980	1,980	1,975
Shares Outstanding (Diluted)	1,973	1,975	1,980	1,980	1,980	1,975
Shares Change (YoY)	-0.17%	-0.25%	-0.02%	0.02%	0.25%	-1.29%
EPS (Basic)	-0.07	-0.15	0.15	0.22	0.34	0.33
EPS (Diluted)	-0.07	-0.15	0.15	0.22	0.34	0.33
EPS Growth	-	-	-30.29%	-35.10%	2.21%	6.45%
Free Cash Flow	1,160	669.02	305.35	1,277	13.19	1,142
Free Cash Flow Per Share	0.59	0.34	0.15	0.65	0.01	0.58
Dividend Per Share	0.200	-	0.220	0.220	0.220	0.220
Dividend Growth	-9.09%	-	-	-	-	-
Gross Margin	33.11%	32.90%	37.83%	39.76%	37.58%	40.52%
Operating Margin	10.14%	9.16%	11.27%	14.17%	11.94%	13.59%
Profit Margin	-1.18%	-2.56%	2.61%	3.28%	5.37%	5.99%
Free Cash Flow Margin	9.79%	5.73%	2.63%	9.65%	0.11%	10.50%
EBITDA	2,179	1,995	2,165	2,647	2,200	2,175
EBITDA Margin	18.40%	17.10%	18.67%	20.00%	17.70%	19.99%
D&A For EBITDA	978.26	926.8	858.19	771.15	716.37	696.31
EBIT	1,200	1,068	1,307	1,875	1,484	1,478
EBIT Margin	10.14%	9.16%	11.27%	14.17%	11.94%	13.59%
Effective Tax Rate	130.48%	-	24.14%	30.54%	28.18%	23.18%
Revenue as Reported	11,841	11,665	11,595	13,232	12,431	-
Advertising Expenses	-	410.08	610.81	758.7	887.58	979.61

Source: S&P Global Market Intelligence. Standard template. Financial Sources.